Acute Intermittent Porphyria Market Emerging Audience, Segments, Market Sales, Profits and Regional Study

0
2K

The Global Acute Intermittent Porphyria industry is projected to grow from USD 4.61 Billion in 2024 to USD 7.34 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.90% during the forecast period (2024 - 2032).

The risk factors associated with acute intermittent porphyria, which include liver cancer (hepatocellular carcinoma), kidney failure, neurological disorders, psychiatric issues, gastrointestinal problems, urinary tract issues, etc. will accelerate the market expansion. The growth of the market is also attributable to the increasing prevalence of the metabolic disorders which is likely to increase further during the assessment period.

Other factors responsible for the market proliferation include developments in the healthcare sector, adoption of latest technologies for diagnosis, drug discoveries for treatment, clinical trials by key players, increased disposable income, population explosion, etc. However, factors that will restrict the market growth across the assessment period include the availability of expensive treatment and poor reimbursement policies in the developing regions.

 

Market Segmentation:

By diagnosis, the global acute intermittent porphyria market has been segmented into blood test, urine test, serum test, DNA test, and others. 

By treatment, acute intermittent porphyria market is segmented into gonadotropin-releasing hormone analogues, prophylactic hematin infusions, and others.

By end user, the global acute intermittent porphyria market has been segmented into hospitals & clinics, research centers, and others.

Regional Analysis:

By region, the acute intermittent porphyria market has been segmented into North America & South America, Europe, Asia Pacific, and, the Middle East & Africa. The North America & South America region will generate maximum revenue from the market during the projection period. The technological advancements integrated into the treatment of acute intermittent porphyria is likely to accelerate revenue creation over the review period. Other factors responsible for the growth of the market include increasing patient with genetic metabolic disorders, rising healthcare expenditure, and increasing government support for research & development. Furthermore, the concentration of key players in the region coupled with increased research & development activities will encourage the market growth and expansion.

Europe is the second largest market for acute intermittent porphyria globally. The favorable factors supporting the market expansion in the region are initiatives undertaken by the governments and the availability of funds for research & development activities. The presence of developed economies in the region is also likely to propel the market growth.

Asia Pacific will exhibit the steepest rise in growth of the market. The increasing geriatric population in the region is one of the primary drivers of the market. Asian Development Bank has estimated that by 2050, 15% of the total population of Malaysia will be from over 65 years age group, and in China, the aging population will surpass 300 million. Furthermore, the booming healthcare sector, technological developments, huge patient population, high healthcare expenditure, etc. will favor the market proliferation throughout the projection period.

The Middle East & Africa will exhibit sluggish growth due to limited screening, ignorance of diseases, and poor access to treatment.

Competitive Dashboard:

The Acute Intermittent Porphyria Market players profiled by MRFR in its report include Dahaner (U.S.), Bio-Rad Laboratories, Inc.  (U.S.), Siemens AG (U.S.), Sysmex Corporation (Japan), ARKRAY, Inc. (Japan), ACON Laboratories, Inc. (U.S.), and, F. Hoffmann-La Roche Ltd (Switzerland) among others. The players strive to gain prominence in the market by devising and employing strategies such as research & development, clinical trials, acquisitions & mergers, innovative collaborations, agreements, etc.

Industry Developments:

In January 2018, Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, has announced the expansion of Alnylam Act. The program will include free third-party genetic testing and counseling for Acute Hepatic Porphyrias (AHPs) which include four diseases- acute intermittent porphyria, hereditary deficit of delta-aminolevulinic acid dehydratase, hereditary coproporphyria, and, variegate porphyria.

Related Report:

Keytruda Market

 

Cosmetology Market

 

Bacteriophage Market

 

surgical masks Market

 

For More Information, Please Visit @ Market Research Future

Patrocinado
Pesquisar
Patrocinado
Categorias
Leia Mais
Outro
Elevate Your Brand Through Advanced Apps By Leading App Development Company Dubai -Dxb Apps
DXB APPS has proved an excellent app development company Dubai for Dubai app Development....
Por mobileappdevelopmentcompanyinUAE 2025-02-18 15:13:49 0 1K
Outro
GCC Alcoholic Drinks Market Witness Highest Growth at a CAGR of 7.5% by 2030
Quick Overview of the GCC Alcoholic Drinks Market Analysis The recent analytical report...
Por irenegarcia 2025-01-13 08:52:01 0 2K
Outro
Streamline Your Hiring Process with Efficient Background Check Verification of Employment
In today's fast-paced business world, hiring the right employees is essential to creating a...
Por Surescreening123 2024-11-07 10:26:45 0 2K
Health and Wellness
EATING DISORDERS- Technology Is Transforming How We Treat Eating Disorders. Remote treatment for eating disorders may be more efficient and less stressful. Reviewed by Davia Sills
KEY POINTS- Since the COVID-19 pandemic, technology has made online therapy more common....
Por Ikeji 2023-09-14 04:17:51 0 4K
Jogos
Big Mumbai: Where Millions Chase a Dream
Big Mumbai is a classic and highly popular gaming platform, offering an exciting collection of...
Por jihan46454 2025-06-02 11:54:55 0 1K
Patrocinado
google-site-verification: google037b30823fc02426.html